董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan M. Rothberg | 男 | Director | 61 | 未披露 | 未持股 | 2025-12-08 |
| Joseph M. Devivo | 男 | Chairman of the Board, President and Chief Executive Officer | 58 | 未披露 | 未持股 | 2025-12-08 |
| Dawn Carfora | 女 | Independent Director | 53 | 未披露 | 未持股 | 2025-12-08 |
| Larry M. Robbins | 男 | Lead Independent Director | 55 | 未披露 | 未持股 | 2025-12-08 |
| Erica G. Schwartz | 女 | Independent Director | 53 | 未披露 | 未持股 | 2025-12-08 |
| Elazer Edelman | 男 | Independent Director | 68 | 未披露 | 未持股 | 2025-12-08 |
| S. Louise Phanstiel | 女 | Independent Director | 66 | 未披露 | 未持股 | 2025-12-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Doherty | 男 | Executive Vice President and Chief Financial Officer | 60 | 未披露 | 未持股 | 2025-12-08 |
| Joseph M. Devivo | 男 | Chairman of the Board, President and Chief Executive Officer | 58 | 未披露 | 未持股 | 2025-12-08 |
| Steven Cashman | 男 | Chief Business Officer | 48 | 未披露 | 未持股 | 2025-12-08 |
| Andrei G. Stoica | 男 | Chief Technology Officer | 52 | 未披露 | 未持股 | 2025-12-08 |
| Megan Carlson | 女 | Interim Chief Financial Officer,Chief Accounting Officer and Senior Vice President of Finance | 42 | 未披露 | 未持股 | 2025-12-08 |
董事简历
中英对照 | 中文 | 英文- Jonathan M. Rothberg
-
是Legacy Quantum-Si的创始人，自2021年6月完成业务合并以来一直担任Quantum-Si Incorporated董事会主席。Rothberg博士还在2022年2月至2022年10月期间担任Quantum-Si Incorporated临时首席执行官。Rothberg博士自2015年12月起担任Legacy Quantum-Si执行主席。他曾于2015年12月至2020年11月担任Legacy Quantum-Si的首席执行官。罗斯伯格博士是一位科学家和企业家，他因发明并商业化高速DNA测序技术而被奥巴马总统授予美国国家技术与创新奖章，这是美国在技术成就方面的最高荣誉。Rothberg博士是4C医疗技术孵化器的创始人，也是其公司的创始人和董事长：Quantum-Si、Butterfly Network, Inc.、AI Therapeutics，Inc.（前身为LAM Therapeutics，Inc.）、Hyperfine, Inc.、identifeye Health Inc.（前身为Tesseract Health，Inc.）、Liminal Sciences，Inc.（前身为EpilepsyCo Inc.）、Detect，Inc.（前身为Homodeus Inc.）和Protein Evolution，Inc.。这些公司专注于Quantum-Si Incorporated医学领域的拐点，如深度学习、下一代测序和硅供应链，以应对全球医疗保健挑战。Rothberg博士曾于2007年至2010年创立和担任Ion Torrent Systems，Inc.的董事长、首席执行官和首席技术官，并于2004年至2009年创立和担任RainDance Technologies，Inc.的董事长和首席执行官。1999年至2007年，Rothberg博士与他人共同创立了ClarifI公司，并担任其董事长。1999年至2006年，他创立了454生命科学公司，并担任其董事长、首席执行官和首席技术官。罗斯伯格博士在《454生命科学》杂志上推出了自1980年桑格和吉尔伯特凭借他们的方法获得诺贝尔奖以来的第一个基因组测序新方法。利用454的技术，罗斯伯格博士测序了第一个人类个体基因组，并与斯万特·帕博（Svante Paabo）一起发起了第一个大规模的古DNA测序计划（The Neanderthal Genome Project）。在454生命科学公司之前，Rothberg博士创立了CuraGen公司，并于1993年至2004年担任该公司董事长兼首席执行官。他在基因组测序领域的贡献包括第一个非细菌克隆方法（通过有限稀释进行克隆）和第一个大规模平行DNA测序方法（通过在单一底物上合成进行平行测序），这些概念构成了所有后续下一代测序技术的基础。罗斯伯格博士是安永年度企业家奖，曾获得《华尔街日报》首届创新金奖、SXSW最佳表演奖、Nature Methods First Method of the Year奖、康涅狄格技术奖章、DGKL生化分析奖，以及西奈山荣誉科学博士学位。罗斯伯格博士是美国国家工程院、康涅狄格科学与工程院的成员，也是卡内基梅隆大学的受托人和耶鲁大学的遗传学兼职教授。Rothberg博士担任Butterfly Network公司董事会主席和Hyperfine, Inc.董事会成员。Rothberg博士在耶鲁大学获得生物学博士、哲学硕士和理学硕士学位，在卡内基梅隆大学获得化学工程学士学位。
Jonathan M. Rothberg,is the founder of Legacy Butterfly and served as the Interim Chief Executive Officer from December 2022 to April 2023. Dr. Rothberg is a member of board of directors and served as the Chairperson of board of directors from the closing of the Business Combination in February 2021 to April 2023. Dr. Rothberg served as the Chairman of Legacy Butterfly's board of directors from March 2014 to February 2021. He previously served as Legacy Butterfly's Chief Executive Officer from March 2014 to April 2020, and as Legacy Butterfly's President from March 2014 to April 2014. Dr. Rothberg is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation's highest honor for technological achievement, by President Obama for inventing and commercializing high-speed DNA sequencing. Dr. Rothberg is the founder of the 4Catalyzer medical technology incubator and the founder of its companies: Legacy Butterfly, AI Therapeutics, Inc. (formerly LAM Therapeutics, Inc.), Quantum-Si Incorporated (Nasdaq: QSI), Hyperfine, Inc. (Nasdaq: HYPR), including its wholly-owned subsidiaries Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Liminal Sciences, Inc., Tesseract Health, Inc., Detect, Inc. (formerly Homodeus Inc.) and 4Bionics LLC. These companies focus on Butterfly Network, Inc. ing inflection points in medicine, such as deep learning, next-generation sequencing, and the silicon supply chain, to address global healthcare challenges. Dr. Rothberg serves as Interim Chief Executive Officer and Executive Chairman of the board of Quantum-Si Incorporated (Nasdaq: QSI) and Vice Chairman of Hyperfine, Inc. (Nasdaq: HYPR). Dr. Rothberg previously founded and served as Chairman, Chief Executive Officer, and Chief Technology Officer of Ion Torrent Systems, Inc. from 2007 to 2010, and founded and served as Chairman and Chief Executive Officer of RainDance Technologies, Inc. from 2004 to 2009. From 1999 to 2007, Dr. Rothberg co-founded and served as Chairman of ClarifI, Inc., and from 1999 to 2006, he founded and served as Chairman, Chief Executive Officer and Chief Technology Officer of 454 Life Sciences Corporation ("454 Life Sciences"). With 454 Life Sciences, Dr. Rothberg brought to market the first new way to sequence genomes since Sanger and Gilbert won the Nobel Prize for their method in 1980. With 454 Life Sciences' technology, Dr. Rothberg sequenced the first individual human genome, and with Svante Paabo he initiated the first large-scale effort to sequence ancient DNA (The Neanderthal Genome Project). Prior to 454 Life Sciences, Dr. Rothberg founded and served as Chairman and Chief Executive Officer of CuraGen Corporation from 1993 to 2004. His contributions to the field of genome sequencing include the first non-bacterial cloning method (cloning by limited dilution) and the first massively parallel DNA sequencing method (parallel sequencing by synthesis on a single substrate), concepts that have formed the basis for all subsequent next generation sequencing technologies. Dr. Rothberg is an Ernst and Young Entrepreneur of the Year, is the recipient of The Wall Street Journal's First Gold Medal for Innovation, SXSW Best in Show, Nature Methods First Method of the Year Award, the Connecticut Medal of Technology, the DGKL Biochemical Analysis Prize, and an Honorary Doctorate of Science from Mount Sinai. Dr. Rothberg is a member of the National Academy of Engineering, the Connecticut Academy of Science and Engineering, is a trustee of Carnegie Mellon University and an Adjunct Professor of Genetics at Yale University. Dr. Rothberg received his Ph.D., M.Phil., his M.S. in biology from Yale University and his B.S. in chemical engineering from Carnegie Mellon University. - 是Legacy Quantum-Si的创始人，自2021年6月完成业务合并以来一直担任Quantum-Si Incorporated董事会主席。Rothberg博士还在2022年2月至2022年10月期间担任Quantum-Si Incorporated临时首席执行官。Rothberg博士自2015年12月起担任Legacy Quantum-Si执行主席。他曾于2015年12月至2020年11月担任Legacy Quantum-Si的首席执行官。罗斯伯格博士是一位科学家和企业家，他因发明并商业化高速DNA测序技术而被奥巴马总统授予美国国家技术与创新奖章，这是美国在技术成就方面的最高荣誉。Rothberg博士是4C医疗技术孵化器的创始人，也是其公司的创始人和董事长：Quantum-Si、Butterfly Network, Inc.、AI Therapeutics，Inc.（前身为LAM Therapeutics，Inc.）、Hyperfine, Inc.、identifeye Health Inc.（前身为Tesseract Health，Inc.）、Liminal Sciences，Inc.（前身为EpilepsyCo Inc.）、Detect，Inc.（前身为Homodeus Inc.）和Protein Evolution，Inc.。这些公司专注于Quantum-Si Incorporated医学领域的拐点，如深度学习、下一代测序和硅供应链，以应对全球医疗保健挑战。Rothberg博士曾于2007年至2010年创立和担任Ion Torrent Systems，Inc.的董事长、首席执行官和首席技术官，并于2004年至2009年创立和担任RainDance Technologies，Inc.的董事长和首席执行官。1999年至2007年，Rothberg博士与他人共同创立了ClarifI公司，并担任其董事长。1999年至2006年，他创立了454生命科学公司，并担任其董事长、首席执行官和首席技术官。罗斯伯格博士在《454生命科学》杂志上推出了自1980年桑格和吉尔伯特凭借他们的方法获得诺贝尔奖以来的第一个基因组测序新方法。利用454的技术，罗斯伯格博士测序了第一个人类个体基因组，并与斯万特·帕博（Svante Paabo）一起发起了第一个大规模的古DNA测序计划（The Neanderthal Genome Project）。在454生命科学公司之前，Rothberg博士创立了CuraGen公司，并于1993年至2004年担任该公司董事长兼首席执行官。他在基因组测序领域的贡献包括第一个非细菌克隆方法（通过有限稀释进行克隆）和第一个大规模平行DNA测序方法（通过在单一底物上合成进行平行测序），这些概念构成了所有后续下一代测序技术的基础。罗斯伯格博士是安永年度企业家奖，曾获得《华尔街日报》首届创新金奖、SXSW最佳表演奖、Nature Methods First Method of the Year奖、康涅狄格技术奖章、DGKL生化分析奖，以及西奈山荣誉科学博士学位。罗斯伯格博士是美国国家工程院、康涅狄格科学与工程院的成员，也是卡内基梅隆大学的受托人和耶鲁大学的遗传学兼职教授。Rothberg博士担任Butterfly Network公司董事会主席和Hyperfine, Inc.董事会成员。Rothberg博士在耶鲁大学获得生物学博士、哲学硕士和理学硕士学位，在卡内基梅隆大学获得化学工程学士学位。
- Jonathan M. Rothberg,is the founder of Legacy Butterfly and served as the Interim Chief Executive Officer from December 2022 to April 2023. Dr. Rothberg is a member of board of directors and served as the Chairperson of board of directors from the closing of the Business Combination in February 2021 to April 2023. Dr. Rothberg served as the Chairman of Legacy Butterfly's board of directors from March 2014 to February 2021. He previously served as Legacy Butterfly's Chief Executive Officer from March 2014 to April 2020, and as Legacy Butterfly's President from March 2014 to April 2014. Dr. Rothberg is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation's highest honor for technological achievement, by President Obama for inventing and commercializing high-speed DNA sequencing. Dr. Rothberg is the founder of the 4Catalyzer medical technology incubator and the founder of its companies: Legacy Butterfly, AI Therapeutics, Inc. (formerly LAM Therapeutics, Inc.), Quantum-Si Incorporated (Nasdaq: QSI), Hyperfine, Inc. (Nasdaq: HYPR), including its wholly-owned subsidiaries Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Liminal Sciences, Inc., Tesseract Health, Inc., Detect, Inc. (formerly Homodeus Inc.) and 4Bionics LLC. These companies focus on Butterfly Network, Inc. ing inflection points in medicine, such as deep learning, next-generation sequencing, and the silicon supply chain, to address global healthcare challenges. Dr. Rothberg serves as Interim Chief Executive Officer and Executive Chairman of the board of Quantum-Si Incorporated (Nasdaq: QSI) and Vice Chairman of Hyperfine, Inc. (Nasdaq: HYPR). Dr. Rothberg previously founded and served as Chairman, Chief Executive Officer, and Chief Technology Officer of Ion Torrent Systems, Inc. from 2007 to 2010, and founded and served as Chairman and Chief Executive Officer of RainDance Technologies, Inc. from 2004 to 2009. From 1999 to 2007, Dr. Rothberg co-founded and served as Chairman of ClarifI, Inc., and from 1999 to 2006, he founded and served as Chairman, Chief Executive Officer and Chief Technology Officer of 454 Life Sciences Corporation ("454 Life Sciences"). With 454 Life Sciences, Dr. Rothberg brought to market the first new way to sequence genomes since Sanger and Gilbert won the Nobel Prize for their method in 1980. With 454 Life Sciences' technology, Dr. Rothberg sequenced the first individual human genome, and with Svante Paabo he initiated the first large-scale effort to sequence ancient DNA (The Neanderthal Genome Project). Prior to 454 Life Sciences, Dr. Rothberg founded and served as Chairman and Chief Executive Officer of CuraGen Corporation from 1993 to 2004. His contributions to the field of genome sequencing include the first non-bacterial cloning method (cloning by limited dilution) and the first massively parallel DNA sequencing method (parallel sequencing by synthesis on a single substrate), concepts that have formed the basis for all subsequent next generation sequencing technologies. Dr. Rothberg is an Ernst and Young Entrepreneur of the Year, is the recipient of The Wall Street Journal's First Gold Medal for Innovation, SXSW Best in Show, Nature Methods First Method of the Year Award, the Connecticut Medal of Technology, the DGKL Biochemical Analysis Prize, and an Honorary Doctorate of Science from Mount Sinai. Dr. Rothberg is a member of the National Academy of Engineering, the Connecticut Academy of Science and Engineering, is a trustee of Carnegie Mellon University and an Adjunct Professor of Genetics at Yale University. Dr. Rothberg received his Ph.D., M.Phil., his M.S. in biology from Yale University and his B.S. in chemical engineering from Carnegie Mellon University.
- Joseph M. Devivo
-
Joseph M. Devivo，自2023年4月起担任Butterfly Network首席执行官兼董事会主席。DeVivo先生此前曾于2020年7月至2022年4月期间担任Teladoc Health, Inc.（“Teladoc”）（纽约证券交易所代码：TDOC）的医院和健康系统总裁。DeVivo先生在2016年至2020年6月期间担任InTouch Health的首席执行官兼董事，当时该公司被Teladoc收购。在此之前，德维沃先生曾于2011年至2016年担任Angiodynamics Inc.的总裁、首席执行官和董事。他目前也是Quantum Surgical的董事会成员，并且是美国远程医疗协会董事会的财务主管，在Caption Health被GE Healthcare收购之前曾担任Caption Health董事会执行主席。DeVivo先生在里士满大学获得工商管理和市场营销与管理理学学士学位。DeVivo先生在Butterfly Network，Inc.董事会任职的资格包括其重要的执行和董事会领导经验。
Joseph M. Devivo,has served as Chief Executive Officer and Chairperson of Butterfly Network, Inc. board of directors since April 2023. Mr. DeVivo previously served as the President of Hospital and Health Systems for Teladoc Health, Inc. ("Teladoc") (NYSE: TDOC) from July 2020 to April 2022. Mr. DeVivo was the Chief Executive Officer and Director of InTouch Health from 2016 until June 2020, when it was acquired by Teladoc. Prior to that, Mr. DeVivo served as the President, Chief Executive Officer and Director of Angiodynamics Inc. from 2011 to 2016. He is also currently a member of the Board of Directors of Quantum Surgical and is the Treasurer on the board of directors at the American Telemedicine Association and previously served as the Executive Chairman of the board of directors of Caption Health prior to Caption Health's acquisition by GE Healthcare. Mr. DeVivo received his Bachelor of Science degree in Business Administration and Marketing and Management from the University of Richmond. - Joseph M. Devivo，自2023年4月起担任Butterfly Network首席执行官兼董事会主席。DeVivo先生此前曾于2020年7月至2022年4月期间担任Teladoc Health, Inc.（“Teladoc”）（纽约证券交易所代码：TDOC）的医院和健康系统总裁。DeVivo先生在2016年至2020年6月期间担任InTouch Health的首席执行官兼董事，当时该公司被Teladoc收购。在此之前，德维沃先生曾于2011年至2016年担任Angiodynamics Inc.的总裁、首席执行官和董事。他目前也是Quantum Surgical的董事会成员，并且是美国远程医疗协会董事会的财务主管，在Caption Health被GE Healthcare收购之前曾担任Caption Health董事会执行主席。DeVivo先生在里士满大学获得工商管理和市场营销与管理理学学士学位。DeVivo先生在Butterfly Network，Inc.董事会任职的资格包括其重要的执行和董事会领导经验。
- Joseph M. Devivo,has served as Chief Executive Officer and Chairperson of Butterfly Network, Inc. board of directors since April 2023. Mr. DeVivo previously served as the President of Hospital and Health Systems for Teladoc Health, Inc. ("Teladoc") (NYSE: TDOC) from July 2020 to April 2022. Mr. DeVivo was the Chief Executive Officer and Director of InTouch Health from 2016 until June 2020, when it was acquired by Teladoc. Prior to that, Mr. DeVivo served as the President, Chief Executive Officer and Director of Angiodynamics Inc. from 2011 to 2016. He is also currently a member of the Board of Directors of Quantum Surgical and is the Treasurer on the board of directors at the American Telemedicine Association and previously served as the Executive Chairman of the board of directors of Caption Health prior to Caption Health's acquisition by GE Healthcare. Mr. DeVivo received his Bachelor of Science degree in Business Administration and Marketing and Management from the University of Richmond.
- Dawn Carfora
-
Dawn Carfora自2021年2月业务合并完成以来一直担任董事会成员，并自2024年起担任薪酬委员会主席。Carfora女士此前曾于2019年9月至2024年12月期间担任Meta Platforms, Inc.（原Facebook, Inc.）（“Meta”）（纳斯达克：META）全球业务集团业务规划和运营副总裁。在此之前，Carfora女士在Meta担任过多个高级领导职务，包括2017年10月至2019年9月担任GMS运营（全球销售运营）总监，2014年3月至2017年10月担任北美销售运营总监。Carfora女士此前于2013年11月至2014年3月担任MagPlus Inc.的首席财务官。在加入MagPlus之前，从2007年5月到2013年11月，她在PDR Network，LLC（“PDR”）担任过多个高级领导职务。在加入PDR之前，Carfora女士曾在MediZine Inc.、普莱媒体、二十世纪福克斯家庭娱乐公司、安永会计师事务所和贝塔斯曼证券公司担任过越来越多的职务。Carfora女士在莱德大学获得了工商管理和金融学士学位。Carfora女士担任董事会成员的资格包括她在管理、财务、业务规划和运营方面的丰富经验。
Dawn Carfora,has served on board of directors since the closing of the Business Combination in February 2021 and serves as the Chair of compensation committee since 2024. Ms. Carfora previously served as Vice President, Business Planning and Operations, Global Business Group of Meta Platforms, Inc. (formerly Facebook, Inc.) ("Meta") (Nasdaq: META) from September 2019 through December 2024. Prior to that, Ms. Carfora held a variety of senior leadership roles at Meta, including as Director, GMS Operations (Global Sales Operations) from October 2017 to September 2019 and as Director, Sales Operations, North America from March 2014 to October 2017. Ms. Carfora previously served as Chief Financial Officer of MagPlus Inc. from November 2013 to March 2014. Prior to MagPlus, from May 2007 to November 2013, she held various senior leadership positions at PDR Network, LLC ("PDR"). Before joining PDR, Ms. Carfora held various roles of increasing responsibility at MediZine Inc., Primedia Inc., Twentieth Century Fox Home Entertainment, Inc., Ernst & Young LLP and Bertelsmann SE & Co. Ms. Carfora received her B.S. in business administration, finance from Rider University. - Dawn Carfora自2021年2月业务合并完成以来一直担任董事会成员，并自2024年起担任薪酬委员会主席。Carfora女士此前曾于2019年9月至2024年12月期间担任Meta Platforms, Inc.（原Facebook, Inc.）（“Meta”）（纳斯达克：META）全球业务集团业务规划和运营副总裁。在此之前，Carfora女士在Meta担任过多个高级领导职务，包括2017年10月至2019年9月担任GMS运营（全球销售运营）总监，2014年3月至2017年10月担任北美销售运营总监。Carfora女士此前于2013年11月至2014年3月担任MagPlus Inc.的首席财务官。在加入MagPlus之前，从2007年5月到2013年11月，她在PDR Network，LLC（“PDR”）担任过多个高级领导职务。在加入PDR之前，Carfora女士曾在MediZine Inc.、普莱媒体、二十世纪福克斯家庭娱乐公司、安永会计师事务所和贝塔斯曼证券公司担任过越来越多的职务。Carfora女士在莱德大学获得了工商管理和金融学士学位。Carfora女士担任董事会成员的资格包括她在管理、财务、业务规划和运营方面的丰富经验。
- Dawn Carfora,has served on board of directors since the closing of the Business Combination in February 2021 and serves as the Chair of compensation committee since 2024. Ms. Carfora previously served as Vice President, Business Planning and Operations, Global Business Group of Meta Platforms, Inc. (formerly Facebook, Inc.) ("Meta") (Nasdaq: META) from September 2019 through December 2024. Prior to that, Ms. Carfora held a variety of senior leadership roles at Meta, including as Director, GMS Operations (Global Sales Operations) from October 2017 to September 2019 and as Director, Sales Operations, North America from March 2014 to October 2017. Ms. Carfora previously served as Chief Financial Officer of MagPlus Inc. from November 2013 to March 2014. Prior to MagPlus, from May 2007 to November 2013, she held various senior leadership positions at PDR Network, LLC ("PDR"). Before joining PDR, Ms. Carfora held various roles of increasing responsibility at MediZine Inc., Primedia Inc., Twentieth Century Fox Home Entertainment, Inc., Ernst & Young LLP and Bertelsmann SE & Co. Ms. Carfora received her B.S. in business administration, finance from Rider University.
- Larry M. Robbins
-
Larry M. Robbins，自2021年2月起担任董事会成员，担任首席独立董事。Robbins先生从成立到2021年2月一直是Longview的董事长。自2024年11月起，他在西维斯健康公司（NYSE：CVS）的董事会任职。Robbins先生是Glenview Capital Management（“Glenview”）的创始人、投资组合经理和首席执行官。在2000年创立Glenview之前，Robbins先生在Omega Advisors（简称“Omega”）的美国股票多头/空头团队担任了六年的分析师和合伙人。他在纽约的并购咨询精品店Gleacher & Company工作了三年后加入了欧米茄。通过他们的罗宾斯家庭基金会，罗宾斯先生和他的妻子萨拉赫迈是纽约市和全国教育改革的积极支持者。他担任Array Education and the Knowledge Is Power Program（KIPP）New York董事会主席，是Relay Graduate School of Education、Robin Hood Foundation和Zearn的董事会成员。此外，Robbins先生还是UJA-联合会华尔街分部的高级主席。罗宾斯先生于1992年以优异的成绩毕业于宾夕法尼亚大学沃顿商学院和摩尔学院，在那里他获得了经济学和工程学学士学位，主修会计、金融、市场营销和系统工程。罗宾斯先生也是一名注册会计师。Robbins先生担任董事会成员的资格包括其广泛的财务会计知识和丰富的投资经验。
Larry M. Robbins,has served on board of directors since February 2021 and serves as Lead Independent Director. Mr. Robbins was Longview's Chairman from its inception to February 2021. Since November 2024, he has served on the board of directors of CVS Health Corporation (NYSE: CVS). Mr. Robbins is the Founder, Portfolio Manager and Chief Executive Officer of Glenview Capital Management ("Glenview"). Prior to founding Glenview in 2000, Mr. Robbins spent six years as an analyst and partner at Omega Advisors ("Omega") on their U.S. equity long/short team. He joined Omega after three years at Gleacher & Company, a merger and acquisition advisory boutique in New York. Through their Robbins Family Foundation, Mr. Robbins and his wife Sarahmay are active supporters of education reform both in New York City and on a national level. He serves as Chairman of the board of directors for Array Education and the Knowledge Is Power Program (KIPP) New York, and he is a board member for the Relay Graduate School of Education, Robin Hood Foundation and Zearn. In addition, Mr. Robbins is the Senior Chair of the Wall Street Division of the UJA-Federation. Mr. Robbins graduated with honors from the Wharton School and Moore School of the University of Pennsylvania in 1992, where he received his B.S. in Economics and Engineering, with majors in accounting, finance, marketing, and systems engineering. Mr. Robbins is also a certified public accountant. - Larry M. Robbins，自2021年2月起担任董事会成员，担任首席独立董事。Robbins先生从成立到2021年2月一直是Longview的董事长。自2024年11月起，他在西维斯健康公司（NYSE：CVS）的董事会任职。Robbins先生是Glenview Capital Management（“Glenview”）的创始人、投资组合经理和首席执行官。在2000年创立Glenview之前，Robbins先生在Omega Advisors（简称“Omega”）的美国股票多头/空头团队担任了六年的分析师和合伙人。他在纽约的并购咨询精品店Gleacher & Company工作了三年后加入了欧米茄。通过他们的罗宾斯家庭基金会，罗宾斯先生和他的妻子萨拉赫迈是纽约市和全国教育改革的积极支持者。他担任Array Education and the Knowledge Is Power Program（KIPP）New York董事会主席，是Relay Graduate School of Education、Robin Hood Foundation和Zearn的董事会成员。此外，Robbins先生还是UJA-联合会华尔街分部的高级主席。罗宾斯先生于1992年以优异的成绩毕业于宾夕法尼亚大学沃顿商学院和摩尔学院，在那里他获得了经济学和工程学学士学位，主修会计、金融、市场营销和系统工程。罗宾斯先生也是一名注册会计师。Robbins先生担任董事会成员的资格包括其广泛的财务会计知识和丰富的投资经验。
- Larry M. Robbins,has served on board of directors since February 2021 and serves as Lead Independent Director. Mr. Robbins was Longview's Chairman from its inception to February 2021. Since November 2024, he has served on the board of directors of CVS Health Corporation (NYSE: CVS). Mr. Robbins is the Founder, Portfolio Manager and Chief Executive Officer of Glenview Capital Management ("Glenview"). Prior to founding Glenview in 2000, Mr. Robbins spent six years as an analyst and partner at Omega Advisors ("Omega") on their U.S. equity long/short team. He joined Omega after three years at Gleacher & Company, a merger and acquisition advisory boutique in New York. Through their Robbins Family Foundation, Mr. Robbins and his wife Sarahmay are active supporters of education reform both in New York City and on a national level. He serves as Chairman of the board of directors for Array Education and the Knowledge Is Power Program (KIPP) New York, and he is a board member for the Relay Graduate School of Education, Robin Hood Foundation and Zearn. In addition, Mr. Robbins is the Senior Chair of the Wall Street Division of the UJA-Federation. Mr. Robbins graduated with honors from the Wharton School and Moore School of the University of Pennsylvania in 1992, where he received his B.S. in Economics and Engineering, with majors in accounting, finance, marketing, and systems engineering. Mr. Robbins is also a certified public accountant.
- Erica G. Schwartz
-
Erica G. Schwartz，自2021年9月起担任董事会成员，担任提名和公司治理委员会主席。Schwartz博士自2021年10月起担任United Healthcare保险解决方案总裁。此前，施瓦茨博士曾于2019年3月至2021年4月担任美国卫生与公众服务部副外科医生，在那里她领导了美国应对新冠肺炎大流行的公共卫生部署。在担任副外科医生之前，施瓦茨医生在军警服役了24年，在此期间，她通过军衔晋升为美国海岸警卫队少将，并在2015年至2019年期间担任首席医疗官和健康、安全和工作生活主任。此前，施瓦茨博士曾于2013年至2015年担任美国海岸警卫队卫生服务主管，并于2005年至2013年担任预防医学主管。Schwartz博士自2021年5月起担任Aveanna Healthcare Holdings Inc.（纳斯达克：医疗保健）的董事会成员，该公司是一家提供范围广泛的儿科和成人TERM3服务的公司。Schwartz博士接受过预防医学方面的培训和董事会认证。曾获布朗大学生物医学工程理学学士学位、布朗大学医学院医学博士学位、公共卫生硕士学位，双重专注于卫生服务
Erica G. Schwartz,has served on board of directors since September 2021 and serves as the Chair of nominating and corporate governance committee. Dr. Schwartz has served as President of Insurance Solutions at United Healthcare since October 2021. Previously, Dr. Schwartz served as the Deputy Surgeon General for the U.S. Department of Health and Human Services from March 2019 to April 2021, where she led the country's public health deployment in response to the COVID-19 pandemic. Prior to her role as the Deputy Surgeon General, Dr. Schwartz spent 24 years in the uniformed service, during which time she was promoted through the ranks to Rear Admiral of the U.S. Coast Guard, where she served as the Chief Medical Officer and Director of Health, Safety, and Work Life from 2015 to 2019. Previously, Dr. Schwartz served as the U.S. Coast Guard's Chief of Health Services from 2013 to 2015 and Preventive Medicine Chief from 2005 to 2013. Dr. Schwartz has served on the board of directors of Aveanna Healthcare Holdings Inc. (Nasdaq: AVAH), a provider of a broad range of pediatric and adult healthcare services, since May 2021. Dr. Schwartz is trained and board certified in Preventive Medicine. She received a Bachelor of Science degree in Biomedical Engineering from Brown University, a Medical Doctorate from Brown University School of Medicine, a Master of Public Health degree with a dual concentration in health services. - Erica G. Schwartz，自2021年9月起担任董事会成员，担任提名和公司治理委员会主席。Schwartz博士自2021年10月起担任United Healthcare保险解决方案总裁。此前，施瓦茨博士曾于2019年3月至2021年4月担任美国卫生与公众服务部副外科医生，在那里她领导了美国应对新冠肺炎大流行的公共卫生部署。在担任副外科医生之前，施瓦茨医生在军警服役了24年，在此期间，她通过军衔晋升为美国海岸警卫队少将，并在2015年至2019年期间担任首席医疗官和健康、安全和工作生活主任。此前，施瓦茨博士曾于2013年至2015年担任美国海岸警卫队卫生服务主管，并于2005年至2013年担任预防医学主管。Schwartz博士自2021年5月起担任Aveanna Healthcare Holdings Inc.（纳斯达克：医疗保健）的董事会成员，该公司是一家提供范围广泛的儿科和成人TERM3服务的公司。Schwartz博士接受过预防医学方面的培训和董事会认证。曾获布朗大学生物医学工程理学学士学位、布朗大学医学院医学博士学位、公共卫生硕士学位，双重专注于卫生服务
- Erica G. Schwartz,has served on board of directors since September 2021 and serves as the Chair of nominating and corporate governance committee. Dr. Schwartz has served as President of Insurance Solutions at United Healthcare since October 2021. Previously, Dr. Schwartz served as the Deputy Surgeon General for the U.S. Department of Health and Human Services from March 2019 to April 2021, where she led the country's public health deployment in response to the COVID-19 pandemic. Prior to her role as the Deputy Surgeon General, Dr. Schwartz spent 24 years in the uniformed service, during which time she was promoted through the ranks to Rear Admiral of the U.S. Coast Guard, where she served as the Chief Medical Officer and Director of Health, Safety, and Work Life from 2015 to 2019. Previously, Dr. Schwartz served as the U.S. Coast Guard's Chief of Health Services from 2013 to 2015 and Preventive Medicine Chief from 2005 to 2013. Dr. Schwartz has served on the board of directors of Aveanna Healthcare Holdings Inc. (Nasdaq: AVAH), a provider of a broad range of pediatric and adult healthcare services, since May 2021. Dr. Schwartz is trained and board certified in Preventive Medicine. She received a Bachelor of Science degree in Biomedical Engineering from Brown University, a Medical Doctorate from Brown University School of Medicine, a Master of Public Health degree with a dual concentration in health services.
- Elazer Edelman
-
Elazer Edelman，自2021年3月起担任董事会成员，并担任技术委员会主席。Edelman博士曾担任1993年加入的麻省理工学院医学工程和科学的Edward J. Poitras教授、1989年加入的哈佛医学院的医学教授，以及自1984年以来与他有联系的波士顿布莱根妇女医院冠脉护理单元的高级主治医师。他和他的实验室在血管生物学以及生物技术的开发和评估方面开创了基本发现。埃德尔曼博士曾指导麻省理工学院医学工程研究所和科学与临床研究中心以及哈佛-麻省理工学院生物医学工程中心，所有这些都致力于应用物理科学的严谨性来阐明疾病的基本生物过程和机制。他是创始人，自2019年起担任Autus Valve Technologies，Inc.董事会成员，自2015年起担任BioDevek，Inc.董事会成员，自2014年起担任PanTher Therapeutics，LLC董事会成员。Edelman博士在布莱根妇女医院完成了内科医学培训和心血管医学临床研究金，并在哈佛医学院病理学系完成了研究奖学金。Edelman博士获得了哈佛医学院的医学博士学位和医学工程和医学物理博士学位，电气工程和计算机科学硕士学位，以及麻省理工学院的生物电气工程和应用生物学学士学位。Edelman博士担任董事会成员的资格包括他的医疗和生物医学工程背景以及他丰富的科学咨询经验和共同创立了多家技术公司。
Elazer Edelman,has served on board of directors since March 2021 and serves as the Chair of technology committee. Dr. Edelman has served as the Edward J. Poitras Professor in Medical Engineering and Science at the Massachusetts Institute of Technology which he joined in 1993, Professor of Medicine at Harvard Medical School which he joined in 1989, and Senior Attending Physician in the coronary care unit at the Brigham and Women's Hospital in Boston with which he has been associated since 1984. He and his laboratory have pioneered basic findings in vascular biology and the development and assessment of biotechnology. Dr. Edelman has directed the Massachusetts Institute of Technology's Institute for Medical Engineering and Science and Clinical Research Center as well as the Harvard-MIT Biomedical Engineering Center, all dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease. He is the founder and has served on the board of director of Autus Valve Technologies, Inc. since 2019, BioDevek, Inc. since 2015, and PanTher Therapeutics, LLC since 2014. Dr. Edelman completed internal medicine training and clinical fellowship in Cardiovascular Medicine at the Brigham and Women's Hospital and a research fellowship at the Department of Pathology at Harvard Medical School. Dr. Edelman received his M.D. from Harvard Medical School and his Ph.D. in Medical Engineering and Medical Physics, M.S. in Electrical Engineering and Computer Science, and B.S. in Bioelectrical Engineering and Applied Biology from the Massachusetts Institute of Technology. - Elazer Edelman，自2021年3月起担任董事会成员，并担任技术委员会主席。Edelman博士曾担任1993年加入的麻省理工学院医学工程和科学的Edward J. Poitras教授、1989年加入的哈佛医学院的医学教授，以及自1984年以来与他有联系的波士顿布莱根妇女医院冠脉护理单元的高级主治医师。他和他的实验室在血管生物学以及生物技术的开发和评估方面开创了基本发现。埃德尔曼博士曾指导麻省理工学院医学工程研究所和科学与临床研究中心以及哈佛-麻省理工学院生物医学工程中心，所有这些都致力于应用物理科学的严谨性来阐明疾病的基本生物过程和机制。他是创始人，自2019年起担任Autus Valve Technologies，Inc.董事会成员，自2015年起担任BioDevek，Inc.董事会成员，自2014年起担任PanTher Therapeutics，LLC董事会成员。Edelman博士在布莱根妇女医院完成了内科医学培训和心血管医学临床研究金，并在哈佛医学院病理学系完成了研究奖学金。Edelman博士获得了哈佛医学院的医学博士学位和医学工程和医学物理博士学位，电气工程和计算机科学硕士学位，以及麻省理工学院的生物电气工程和应用生物学学士学位。Edelman博士担任董事会成员的资格包括他的医疗和生物医学工程背景以及他丰富的科学咨询经验和共同创立了多家技术公司。
- Elazer Edelman,has served on board of directors since March 2021 and serves as the Chair of technology committee. Dr. Edelman has served as the Edward J. Poitras Professor in Medical Engineering and Science at the Massachusetts Institute of Technology which he joined in 1993, Professor of Medicine at Harvard Medical School which he joined in 1989, and Senior Attending Physician in the coronary care unit at the Brigham and Women's Hospital in Boston with which he has been associated since 1984. He and his laboratory have pioneered basic findings in vascular biology and the development and assessment of biotechnology. Dr. Edelman has directed the Massachusetts Institute of Technology's Institute for Medical Engineering and Science and Clinical Research Center as well as the Harvard-MIT Biomedical Engineering Center, all dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease. He is the founder and has served on the board of director of Autus Valve Technologies, Inc. since 2019, BioDevek, Inc. since 2015, and PanTher Therapeutics, LLC since 2014. Dr. Edelman completed internal medicine training and clinical fellowship in Cardiovascular Medicine at the Brigham and Women's Hospital and a research fellowship at the Department of Pathology at Harvard Medical School. Dr. Edelman received his M.D. from Harvard Medical School and his Ph.D. in Medical Engineering and Medical Physics, M.S. in Electrical Engineering and Computer Science, and B.S. in Bioelectrical Engineering and Applied Biology from the Massachusetts Institute of Technology.
- S. Louise Phanstiel
-
S. Louise Phanstiel，自2021年2月业务合并完成后担任董事会成员，并担任审计委员会主席。Phanstiel女士自2020年3月起担任Myriad Genetics, Inc.（纳斯达克：MYGN）或Myriad的董事会主席，并自2009年9月起担任Myriad的董事。Phanstiel女士此前曾于1996年至2007年在Elevance Health, Inc.（NYSE：ELV）（前身为Anthem，Inc.，在此之前为WellPoint，Inc.）担任多个高管职务。Phanstiel女士曾任特种产品总裁，其中包括行为健康服务；董事长办公室高级副总裁、参谋长和企业规划；WellPoint，Inc.所有子公司的首席会计官、财务总监兼首席财务官。此前，Phanstiel女士是国际服务公司普华永道会计师事务所（PricewaterhouseCoopers，LLP）的合伙人。Phanstiel女士的生命科学经验包括曾在上市公司Inveresk Research Group，Inc.和Verastem Oncology（纳斯达克：VSTM）担任董事会成员和审计委员会主席。Phanstiel女士获得了金门大学会计学学士学位，是一名注册会计师，还持有卡内基梅隆大学网络安全监督专业的CERT认证。
S. Louise Phanstiel,has served on board of directors since the closing of the Business Combination in February 2021 and serves as the Chair of audit committee. Ms. Phanstiel serves as Chair of the Board of Directors of Myriad Genetics, Inc. (Nasdaq: MYGN), or Myriad, since March 2020 and has been a Director of Myriad since September 2009. Ms. Phanstiel previously held several executive positions at Elevance Health, Inc. (NYSE: ELV), formerly Anthem, Inc. and prior to that, WellPoint, Inc., from 1996 to 2007. Ms. Phanstiel was President, Specialty Products, which included behavioral health services; Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries. Previously, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP, formerly Coopers & Lybrand, LLP, where she specialized in insurance. Ms. Phanstiel's life science experience includes having previously served on the board of directors and Chair of the Audit Committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem Oncology (Nasdaq: VSTM). Ms. Phanstiel received her B.A. in Accounting from Golden Gate University, is a Certified Public Accountant, and also holds a CERT certification in cybersecurity oversight from Carnegie Mellon. - S. Louise Phanstiel，自2021年2月业务合并完成后担任董事会成员，并担任审计委员会主席。Phanstiel女士自2020年3月起担任Myriad Genetics, Inc.（纳斯达克：MYGN）或Myriad的董事会主席，并自2009年9月起担任Myriad的董事。Phanstiel女士此前曾于1996年至2007年在Elevance Health, Inc.（NYSE：ELV）（前身为Anthem，Inc.，在此之前为WellPoint，Inc.）担任多个高管职务。Phanstiel女士曾任特种产品总裁，其中包括行为健康服务；董事长办公室高级副总裁、参谋长和企业规划；WellPoint，Inc.所有子公司的首席会计官、财务总监兼首席财务官。此前，Phanstiel女士是国际服务公司普华永道会计师事务所（PricewaterhouseCoopers，LLP）的合伙人。Phanstiel女士的生命科学经验包括曾在上市公司Inveresk Research Group，Inc.和Verastem Oncology（纳斯达克：VSTM）担任董事会成员和审计委员会主席。Phanstiel女士获得了金门大学会计学学士学位，是一名注册会计师，还持有卡内基梅隆大学网络安全监督专业的CERT认证。
- S. Louise Phanstiel,has served on board of directors since the closing of the Business Combination in February 2021 and serves as the Chair of audit committee. Ms. Phanstiel serves as Chair of the Board of Directors of Myriad Genetics, Inc. (Nasdaq: MYGN), or Myriad, since March 2020 and has been a Director of Myriad since September 2009. Ms. Phanstiel previously held several executive positions at Elevance Health, Inc. (NYSE: ELV), formerly Anthem, Inc. and prior to that, WellPoint, Inc., from 1996 to 2007. Ms. Phanstiel was President, Specialty Products, which included behavioral health services; Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries. Previously, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP, formerly Coopers & Lybrand, LLP, where she specialized in insurance. Ms. Phanstiel's life science experience includes having previously served on the board of directors and Chair of the Audit Committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem Oncology (Nasdaq: VSTM). Ms. Phanstiel received her B.A. in Accounting from Golden Gate University, is a Certified Public Accountant, and also holds a CERT certification in cybersecurity oversight from Carnegie Mellon.
高管简历
中英对照 | 中文 | 英文- John Doherty
John Doherty于2018年11月1日加入InterXion担任首席财务官，负责为公司战略和发展活动以及整体财务运营提供领导。他从Verizon加入，在过去的20年中，他曾担任多个高级管理职位，包括2012年至2018年担任Verizon Ventures企业发展高级副总裁，和总裁兼首席投资官。他也是Verizon共享服务、企业和国际组织的首席财务官。他此前曾任职TelecomAsia公司（曼谷），以及NYNEX Cablecomms公司（英国）。Doherty先生拥有斯托尼布鲁克大学（Stonybrook University）的经济学学位，并参加了巴鲁克学院（Baruch College）的工商管理硕士课程以及沃顿商学院（Wharton&8217；s）的高管教育课程。
John Doherty serves as an independent director. Mr. Doherty has 35 years of experience in corporate development, strategic planning, mergers & acquisitions, transaction execution & integration, venture capital investments and financial management in the technology, connectivity and digital infrastructure industries across the United States, Europe, Central America, South America and Asia. Since October 2020 Mr. Doherty has served as the Chief Financial Officer of Magic Leap, an augmented reality AR company pioneering a wearable platform to amplify enterprise productivity, where he is responsible for all strategic, financial and corporate development activity for the company including accounting and control, financial planning & analysis, treasury, fundraising and investor relations. Prior to Magic Leap, from November 2018 to April 2020 Mr. Doherty lived in Amsterdam where he served as the Chief Financial Officer of InterXion (NYSE: INXN), which was a leading provider of cloud and carrier-neutral colocation data center services in Europe. He also led the strategic transaction resulting in InterXion's combination with Digital Realty Trust Inc. (NYSE: DLR), a real estate investment trust that invests in carrier-neutral data centers and provides colocation and peering services, in a transaction valued at approximately $8.4 billion of total enterprise value in March 2020. Prior to InterXion, Mr. Doherty spent over 30 years at Verizon Communications Inc. (NYSE: VZ), one of the largest communication technology companies in the world, where he held a variety of roles including SVP of Corporate Development, President & Chief Investment Officer of Verizon Ventures, SVP of Investor Relations and Chief Financial Officer of Verizon Shared Services and International, among others. Mr. Doherty was named #12 on the Global Corporate Venturing 2018 Powerlist and recognized as “The Most Admired Corporate Deal Maker in Telecommunications” by The Deal in 2016 2014 and 2013. Mr. Doherty was also selected as Top Telecom IR Executive 2-years consecutively.- John Doherty于2018年11月1日加入InterXion担任首席财务官，负责为公司战略和发展活动以及整体财务运营提供领导。他从Verizon加入，在过去的20年中，他曾担任多个高级管理职位，包括2012年至2018年担任Verizon Ventures企业发展高级副总裁，和总裁兼首席投资官。他也是Verizon共享服务、企业和国际组织的首席财务官。他此前曾任职TelecomAsia公司（曼谷），以及NYNEX Cablecomms公司（英国）。Doherty先生拥有斯托尼布鲁克大学（Stonybrook University）的经济学学位，并参加了巴鲁克学院（Baruch College）的工商管理硕士课程以及沃顿商学院（Wharton&8217；s）的高管教育课程。
- John Doherty serves as an independent director. Mr. Doherty has 35 years of experience in corporate development, strategic planning, mergers & acquisitions, transaction execution & integration, venture capital investments and financial management in the technology, connectivity and digital infrastructure industries across the United States, Europe, Central America, South America and Asia. Since October 2020 Mr. Doherty has served as the Chief Financial Officer of Magic Leap, an augmented reality AR company pioneering a wearable platform to amplify enterprise productivity, where he is responsible for all strategic, financial and corporate development activity for the company including accounting and control, financial planning & analysis, treasury, fundraising and investor relations. Prior to Magic Leap, from November 2018 to April 2020 Mr. Doherty lived in Amsterdam where he served as the Chief Financial Officer of InterXion (NYSE: INXN), which was a leading provider of cloud and carrier-neutral colocation data center services in Europe. He also led the strategic transaction resulting in InterXion's combination with Digital Realty Trust Inc. (NYSE: DLR), a real estate investment trust that invests in carrier-neutral data centers and provides colocation and peering services, in a transaction valued at approximately $8.4 billion of total enterprise value in March 2020. Prior to InterXion, Mr. Doherty spent over 30 years at Verizon Communications Inc. (NYSE: VZ), one of the largest communication technology companies in the world, where he held a variety of roles including SVP of Corporate Development, President & Chief Investment Officer of Verizon Ventures, SVP of Investor Relations and Chief Financial Officer of Verizon Shared Services and International, among others. Mr. Doherty was named #12 on the Global Corporate Venturing 2018 Powerlist and recognized as “The Most Admired Corporate Deal Maker in Telecommunications” by The Deal in 2016 2014 and 2013. Mr. Doherty was also selected as Top Telecom IR Executive 2-years consecutively.
- Joseph M. Devivo
Joseph M. Devivo，自2023年4月起担任Butterfly Network首席执行官兼董事会主席。DeVivo先生此前曾于2020年7月至2022年4月期间担任Teladoc Health, Inc.（“Teladoc”）（纽约证券交易所代码：TDOC）的医院和健康系统总裁。DeVivo先生在2016年至2020年6月期间担任InTouch Health的首席执行官兼董事，当时该公司被Teladoc收购。在此之前，德维沃先生曾于2011年至2016年担任Angiodynamics Inc.的总裁、首席执行官和董事。他目前也是Quantum Surgical的董事会成员，并且是美国远程医疗协会董事会的财务主管，在Caption Health被GE Healthcare收购之前曾担任Caption Health董事会执行主席。DeVivo先生在里士满大学获得工商管理和市场营销与管理理学学士学位。DeVivo先生在Butterfly Network，Inc.董事会任职的资格包括其重要的执行和董事会领导经验。
Joseph M. Devivo,has served as Chief Executive Officer and Chairperson of Butterfly Network, Inc. board of directors since April 2023. Mr. DeVivo previously served as the President of Hospital and Health Systems for Teladoc Health, Inc. ("Teladoc") (NYSE: TDOC) from July 2020 to April 2022. Mr. DeVivo was the Chief Executive Officer and Director of InTouch Health from 2016 until June 2020, when it was acquired by Teladoc. Prior to that, Mr. DeVivo served as the President, Chief Executive Officer and Director of Angiodynamics Inc. from 2011 to 2016. He is also currently a member of the Board of Directors of Quantum Surgical and is the Treasurer on the board of directors at the American Telemedicine Association and previously served as the Executive Chairman of the board of directors of Caption Health prior to Caption Health's acquisition by GE Healthcare. Mr. DeVivo received his Bachelor of Science degree in Business Administration and Marketing and Management from the University of Richmond.- Joseph M. Devivo，自2023年4月起担任Butterfly Network首席执行官兼董事会主席。DeVivo先生此前曾于2020年7月至2022年4月期间担任Teladoc Health, Inc.（“Teladoc”）（纽约证券交易所代码：TDOC）的医院和健康系统总裁。DeVivo先生在2016年至2020年6月期间担任InTouch Health的首席执行官兼董事，当时该公司被Teladoc收购。在此之前，德维沃先生曾于2011年至2016年担任Angiodynamics Inc.的总裁、首席执行官和董事。他目前也是Quantum Surgical的董事会成员，并且是美国远程医疗协会董事会的财务主管，在Caption Health被GE Healthcare收购之前曾担任Caption Health董事会执行主席。DeVivo先生在里士满大学获得工商管理和市场营销与管理理学学士学位。DeVivo先生在Butterfly Network，Inc.董事会任职的资格包括其重要的执行和董事会领导经验。
- Joseph M. Devivo,has served as Chief Executive Officer and Chairperson of Butterfly Network, Inc. board of directors since April 2023. Mr. DeVivo previously served as the President of Hospital and Health Systems for Teladoc Health, Inc. ("Teladoc") (NYSE: TDOC) from July 2020 to April 2022. Mr. DeVivo was the Chief Executive Officer and Director of InTouch Health from 2016 until June 2020, when it was acquired by Teladoc. Prior to that, Mr. DeVivo served as the President, Chief Executive Officer and Director of Angiodynamics Inc. from 2011 to 2016. He is also currently a member of the Board of Directors of Quantum Surgical and is the Treasurer on the board of directors at the American Telemedicine Association and previously served as the Executive Chairman of the board of directors of Caption Health prior to Caption Health's acquisition by GE Healthcare. Mr. DeVivo received his Bachelor of Science degree in Business Administration and Marketing and Management from the University of Richmond.
- Steven Cashman
Steven Cashman，自2024年9月起担任首席商务官。在这个职位上，Cashman先生负责监督全球销售、营销、产品和企业战略。在加入Butterfly之前，从2021年4月到2023年8月，Cashman先生担任Caption Health的总裁兼首席执行官，在那里他领导了业界首个人工智能驱动的超声平台的开发和商业化，最终被GE Healthcare收购。在Caption Health之前，2018年1月至2020年8月，他在InTouch Health担任首席商务官，负责国内和全球增长、产品开发、市场营销、客户服务和临床服务。除了担任高管职务外，Cashman先生还作为天使投资人和董事会成员积极参与创业社区。他目前在Vista.ai、Sovato和PatientGenie的董事会任职。
Steven Cashman,has served as Chief Business Officer since September 2024. In this capacity, Mr. Cashman oversees global sales, marketing, product and corporate strategy. Prior to joining Butterfly, from April 2021 to August 2023, Mr. Cashman was the President & CEO of Caption Health, where he led the development and commercialization of the industry's first AI-powered ultrasound platform, culminating in its acquisition by GE Healthcare. Before Caption Health, from January 2018 to August 2020, he served as Chief Commercial Officer at InTouch Health, where he was responsible for domestic and global growth, product development, marketing, customer service, and clinical services. In addition to his executive roles, Mr. Cashman is actively involved in the startup community as an angel investor and board member. He currently serves on the boards of Vista.ai, Sovato, and PatientGenie.- Steven Cashman，自2024年9月起担任首席商务官。在这个职位上，Cashman先生负责监督全球销售、营销、产品和企业战略。在加入Butterfly之前，从2021年4月到2023年8月，Cashman先生担任Caption Health的总裁兼首席执行官，在那里他领导了业界首个人工智能驱动的超声平台的开发和商业化，最终被GE Healthcare收购。在Caption Health之前，2018年1月至2020年8月，他在InTouch Health担任首席商务官，负责国内和全球增长、产品开发、市场营销、客户服务和临床服务。除了担任高管职务外，Cashman先生还作为天使投资人和董事会成员积极参与创业社区。他目前在Vista.ai、Sovato和PatientGenie的董事会任职。
- Steven Cashman,has served as Chief Business Officer since September 2024. In this capacity, Mr. Cashman oversees global sales, marketing, product and corporate strategy. Prior to joining Butterfly, from April 2021 to August 2023, Mr. Cashman was the President & CEO of Caption Health, where he led the development and commercialization of the industry's first AI-powered ultrasound platform, culminating in its acquisition by GE Healthcare. Before Caption Health, from January 2018 to August 2020, he served as Chief Commercial Officer at InTouch Health, where he was responsible for domestic and global growth, product development, marketing, customer service, and clinical services. In addition to his executive roles, Mr. Cashman is actively involved in the startup community as an angel investor and board member. He currently serves on the boards of Vista.ai, Sovato, and PatientGenie.
- Andrei G. Stoica
Andrei G. Stoica，自2021年7月起担任首席技术官。Stoica博士加入BioTelemetry，Inc.，于2020年4月至2021年7月担任首席技术官。在该职位上，Stoica博士负责硬件和软件产品开发、产品管理、企业、产品信息技术以及产品制造和分销。在加入BioTelemetry之前，Stoica博士曾在艾昆纬控股公司（“艾昆纬”）（纽约证券交易所代码：IQV）担任过几个领导职务，职责不断增加，从2006年10月到2020年4月，最后一个职位是IT系统开发高级副总裁。在担任这一职务期间，Stoica博士领导了艾昆纬数据云平台的开发。Stoica博士在布加勒斯特理工大学获得计算机科学学士学位，在南卡罗来纳大学获得计算机科学硕士学位。Stoica博士拥有南卡罗来纳大学计算机科学博士学位。
Andrei G. Stoica,has served as Chief Technology Officer since July 2021. Dr. Stoica joined from BioTelemetry, Inc. where he served as the Chief Technology Officer from April 2020 to July 2021. In this role, Dr. Stoica was responsible for hardware and software product development, product management, enterprise, product information technology and product manufacturing and distribution. Prior to his role at BioTelemetry, Dr. Stoica held several leadership roles of increasing responsibility at IQVIA Holdings, Inc. ("IQVIA") (NYSE: IQV), from October 2006 to April 2020, with the last position as Senior Vice President, IT Systems Development. In this role, Dr. Stoica led the development of IQVIA's data cloud platform. Dr. Stoica received his B.S. in Computer Science from Polytechnic University of Bucharest and M.S. in Computer Science from the University of South Carolina. Dr. Stoica holds a Ph.D. in Computer Science from the University of South Carolina.- Andrei G. Stoica，自2021年7月起担任首席技术官。Stoica博士加入BioTelemetry，Inc.，于2020年4月至2021年7月担任首席技术官。在该职位上，Stoica博士负责硬件和软件产品开发、产品管理、企业、产品信息技术以及产品制造和分销。在加入BioTelemetry之前，Stoica博士曾在艾昆纬控股公司（“艾昆纬”）（纽约证券交易所代码：IQV）担任过几个领导职务，职责不断增加，从2006年10月到2020年4月，最后一个职位是IT系统开发高级副总裁。在担任这一职务期间，Stoica博士领导了艾昆纬数据云平台的开发。Stoica博士在布加勒斯特理工大学获得计算机科学学士学位，在南卡罗来纳大学获得计算机科学硕士学位。Stoica博士拥有南卡罗来纳大学计算机科学博士学位。
- Andrei G. Stoica,has served as Chief Technology Officer since July 2021. Dr. Stoica joined from BioTelemetry, Inc. where he served as the Chief Technology Officer from April 2020 to July 2021. In this role, Dr. Stoica was responsible for hardware and software product development, product management, enterprise, product information technology and product manufacturing and distribution. Prior to his role at BioTelemetry, Dr. Stoica held several leadership roles of increasing responsibility at IQVIA Holdings, Inc. ("IQVIA") (NYSE: IQV), from October 2006 to April 2020, with the last position as Senior Vice President, IT Systems Development. In this role, Dr. Stoica led the development of IQVIA's data cloud platform. Dr. Stoica received his B.S. in Computer Science from Polytechnic University of Bucharest and M.S. in Computer Science from the University of South Carolina. Dr. Stoica holds a Ph.D. in Computer Science from the University of South Carolina.
- Megan Carlson
Megan Carlson，于2021年5月加入公司，曾在公司担任多个高级财务职务，包括2023年1月至2024年9月的副总裁、财务总监，2024年9月至2025年6月的财务与会计副总裁，以及自2025年6月起的首席会计官和财务与会计高级副总裁。在加入公司之前，她曾于2011年10月至2021年5月在深思信息服务担任多个高级财务职务，该公司是一家开发和营销临床试验软件即服务的技术公司。Carlson女士此前曾于2010年11月至2011年10月在Deloitte & Touche LLP担任高级顾问，并于2006年9月至2010年10月在Grant Thornton LLP担任高级审计助理和审计助理。Carlson女士在北卡罗来纳大学教堂山分校的Kenan-Flagler商学院获得工商管理理学学士学位和会计学硕士学位，是一名注册会计师。
Megan Carlson,joined the Company in May 2021 and has served in various senior financial roles at the Company, including Vice President, Controller from January 2023 through September 2024, Vice President, Finance & Accounting from September 2024 through June 2025, and Chief Accounting Officer and Senior Vice President, Finance & Accounting since June 2025. Prior to joining the Company, she served in various senior financial roles at Medidata Solutions, a technology company that develops and markets software as a service for clinical trials, from October 2011 through May 2021. Ms. Carlson previously worked as a Senior Consultant at Deloitte & Touche LLP from November 2010 to October 2011, and as a Senior Audit Associate and Audit Associate at Grant Thornton LLP from September 2006 to October 2010. Ms. Carlson received her Bachelor of Science in Business Administration, as well as her Master of Accounting, from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and is a certified public accountant.- Megan Carlson，于2021年5月加入公司，曾在公司担任多个高级财务职务，包括2023年1月至2024年9月的副总裁、财务总监，2024年9月至2025年6月的财务与会计副总裁，以及自2025年6月起的首席会计官和财务与会计高级副总裁。在加入公司之前，她曾于2011年10月至2021年5月在深思信息服务担任多个高级财务职务，该公司是一家开发和营销临床试验软件即服务的技术公司。Carlson女士此前曾于2010年11月至2011年10月在Deloitte & Touche LLP担任高级顾问，并于2006年9月至2010年10月在Grant Thornton LLP担任高级审计助理和审计助理。Carlson女士在北卡罗来纳大学教堂山分校的Kenan-Flagler商学院获得工商管理理学学士学位和会计学硕士学位，是一名注册会计师。
- Megan Carlson,joined the Company in May 2021 and has served in various senior financial roles at the Company, including Vice President, Controller from January 2023 through September 2024, Vice President, Finance & Accounting from September 2024 through June 2025, and Chief Accounting Officer and Senior Vice President, Finance & Accounting since June 2025. Prior to joining the Company, she served in various senior financial roles at Medidata Solutions, a technology company that develops and markets software as a service for clinical trials, from October 2011 through May 2021. Ms. Carlson previously worked as a Senior Consultant at Deloitte & Touche LLP from November 2010 to October 2011, and as a Senior Audit Associate and Audit Associate at Grant Thornton LLP from September 2006 to October 2010. Ms. Carlson received her Bachelor of Science in Business Administration, as well as her Master of Accounting, from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and is a certified public accountant.